IP Verse

Crystalline Form Of (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-Hydropyrazolo[1,5-A]Pyrimidine-3-Carboxamide, Preparation, And Uses Thereof

Patent No. EP3500575 (titled "Crystalline Form Of (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-Hydropyrazolo[1,5-A]Pyrimidine-3-Carboxamide, Preparation, And Uses Thereof") was filed by Beigene on Aug 15, 2017. The application was issued on Feb 25, 2026.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
EGISAug 5, 2026STOLMAR & PARTNER
HAMPTON KNOWLESAug 5, 2026D YOUNG
KERNEBECK PATENTANWALTSAug 5, 2026KERNEBECK
DEVA HOLDINGAug 4, 2026-
SANDOZAug 3, 2026ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3500575

BEIGENE
Application Number
EP17841172A
Filing Date
Aug 15, 2017
Status
Granted And Under Opposition
Oct 3, 2025
Publication Date
Feb 25, 2026
External Links
Slate, Register , Google Patents